Atlas Trials

Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma

Clinical trial NCT05460767 · UNKNOWN

Trial details

NCT number
NCT05460767
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Solid Tumors or Lymphoma
Start date
2022-08-31
Primary completion
2024-03-31
Enrollment
260

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.